Browse by portfolio

Curated collections of public companies.

NYSE-Listed

2045 companies

NASDAQ-Listed

3792 companies

AT-Listed

116 companies

SW-Listed

755 companies

Latest Headlines

Follow companies to personalize your feed

Today

Nexalis Therapeutics LimitedBusiness

Mar26 Appendix 4C Cash Flow Report

in an hour

Platformo LtdBusiness

Quarterly Activities Report and Appendix 4C - March 2026

in an hour

Formosa Pharmaceuticals, Inc.Business

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases

32 minutes ago

Intercontinental Hotels Group PlcBusiness

InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 30

an hour ago

India Capital Growth FundBusiness

Miscellaneous

an hour ago

Antares Metals LimitedBusiness

Quarterly Activities Report - March 2026

an hour ago

Invion LtdBusiness

Appendix 4C and Quarterly Activities Report - March 2026

2 hours ago

Hangzhou Diagens Biotechnology Co., Ltd. Class HBusiness

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

2 hours ago

Ing Groep NvBusiness

ING completes share buyback and announces new programme of up to €1.0 billion

2 hours ago

Argen-xBusiness

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

2 hours ago

Santhera Pharmaceuticals Holding AgBusiness

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

2 hours ago

Arcelormittal SaBusiness

ArcelorMittal S.A.: ArcelorMittal reports first quarter 2026 results

2 hours ago

Star Health And Allied Insurance Company LimitedBusiness

Star Health reports a 16% increase in PAT of INR 911 Crores in FY26 vs FY25; Growth and Operating Metrics improve sharply

2 hours ago

Ing Groep NvBusiness

ING posts 1Q2026 net result of €1,556 million, driven by continued growth in customer balances and fee income

2 hours ago

Pure One Corporation LimitedBusiness

March 2026 Quarterly Report

2 hours ago

Landis+gyr Group AgBusiness

Landis+Gyr Announces Sale of Rhebo to Everfield

3 hours ago

Lazard LtdBusiness

Lazard to Acquire Campbell Lutyens, Creating the Global Leader in Private Capital Advisory

3 hours ago

Mabwell (shanghai) Bioscience Co. Ltd. ABusiness

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

3 hours ago

Astron LimitedBusiness

Appendix 5B - Quarterly Cash Flows - 31 March 2026

3 hours ago

Qingdao Haier Biomedical Co LtdBusiness

Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

3 hours ago

Business

Jan 29 2025

3 min read

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:

	Conference:	Guggenheim SMID Cap Biotech Conference

	Date/Time:	Wednesday, February 5, 2025, at 9:30 a.m. EST

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

Source: Altimmune, Inc